Performance of advanced imaging modalities at diagnosis and treatment response evaluation of patients with post-transplant lymphoproliferative disorder: A systematic review and meta-analysis
VISTA drives macrophages towards a pro-tumoral phenotype that promotes cancer cell phagocytosis yet down-regulates T cell responses.
Autorzy:
Lin Y; Department of Hematology, University Medical Center Groningen (UMCG), University of Groningen, Groningen, 9713 EZ, The Netherlands. Choukrani G; Department of Hematology, University Medical Center Groningen (UMCG), University of Groningen, Groningen, 9713 EZ, The Netherlands. Dubbel L; Faculty VI, School of Medicine and Health Sciences, Department for human Medicine, Carl von Ossietzky Universität Oldenburg, University Clinic for Gynecology, Oldenburg, Germany. Rockstein L; Faculty VI, School of Medicine and Health Sciences, Department for human Medicine, Carl von Ossietzky Universität Oldenburg, University Clinic for Gynecology, Oldenburg, Germany. Freile JA; Department of Hematology, University Medical Center Groningen (UMCG), University of Groningen, Groningen, 9713 EZ, The Netherlands. Qi Y; Department of Hematology, University Medical Center Groningen (UMCG), University of Groningen, Groningen, 9713 EZ, The Netherlands. Wiersma V; Department of Hematology, University Medical Center Groningen (UMCG), University of Groningen, Groningen, 9713 EZ, The Netherlands. Zhang H; Institute of Precision Cancer Medicine and Pathology, Jinan University Medical College, Guangzhou, Guangdong, China. Koch KW; Faculty VI, School of Medicine and Health Sciences, Dept. of Neuroscience, Carl von Ossietzky Universität Oldenburg, Oldenburg, Germany. Ammatuna E; Department of Hematology, University Medical Center Groningen (UMCG), University of Groningen, Groningen, 9713 EZ, The Netherlands. Schuringa JJ; Department of Hematology, University Medical Center Groningen (UMCG), University of Groningen, Groningen, 9713 EZ, The Netherlands. vanMeertenT; Department of Hematology, University Medical Center Groningen (UMCG), University of Groningen, Groningen, 9713 EZ, The Netherlands. Huls G; Department of Hematology, University Medical Center Groningen (UMCG), University of Groningen, Groningen, 9713 EZ, The Netherlands. Bremer E; Department of Hematology, University Medical Center Groningen (UMCG), University of Groningen, Groningen, 9713 EZ, The Netherlands. .
Population-Based External Validation of the EASIX Scores to Predict CAR T-Cell-Related Toxicities.
Autorzy:
de Boer JW; Department of Hematology, University of Groningen, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands. Keijzer K; Department of Hematology, University of Groningen, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands.; Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands. Pennings ERA; Department of Hematology, Amsterdam UMC Location University of Amsterdam, 1007 MB Amsterdam, The Netherlands.; Cancer Center Amsterdam, 1105 AZ Amsterdam, The Netherlands.; LYMMCARE (Lymphoma and Myeloma Center Amsterdam), 1105 AZ Amsterdam, The Netherlands.; Erasmus School of Health Policy and Management, Erasmus University Rotterdam, 3062 PA Rotterdam, The Netherlands. van Doesum JA; Department of Hematology, University of Groningen, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands. Spanjaart AM; Department of Hematology, Amsterdam UMC Location University of Amsterdam, 1007 MB Amsterdam, The Netherlands.; Cancer Center Amsterdam, 1105 AZ Amsterdam, The Netherlands.; LYMMCARE (Lymphoma and Myeloma Center Amsterdam), 1105 AZ Amsterdam, The Netherlands. Jak M; Department of Hematology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands. Mutsaers PGNJ; Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands. van Dorp S; Department of Hematology, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands. Vermaat JSP; Department of Hematology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands. van der Poel MWM; Department of Internal Medicine, Division of Hematology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, 6229 HX Maastricht, The Netherlands. van Dijk LV; Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands. Kersten MJ; Department of Hematology, Amsterdam UMC Location University of Amsterdam, 1007 MB Amsterdam, The Netherlands.; Cancer Center Amsterdam, 1105 AZ Amsterdam, The Netherlands.; LYMMCARE (Lymphoma and Myeloma Center Amsterdam), 1105 AZ Amsterdam, The Netherlands. Niezink AGH; Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands. vanMeertenT; Department of Hematology, University of Groningen, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands.
The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands.
Autorzy:
Spanjaart AM; Department of Hematology, Amsterdam UMC Location University of Amsterdam, 1007 MB Amsterdam, The Netherlands.; Cancer Center Amsterdam, 1105 AZ Amsterdam, The Netherlands.; LYMMCARE (Lymphoma and Myeloma Center Amsterdam), 1105 AZ Amsterdam, The Netherlands. Pennings ERA; Department of Hematology, Amsterdam UMC Location University of Amsterdam, 1007 MB Amsterdam, The Netherlands.; Cancer Center Amsterdam, 1105 AZ Amsterdam, The Netherlands.; LYMMCARE (Lymphoma and Myeloma Center Amsterdam), 1105 AZ Amsterdam, The Netherlands.; Erasmus School of Health Policy and Management, Erasmus University Rotterdam, 3062 PA Rotterdam, The Netherlands. Mutsaers PGNJ; Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands. van Dorp S; Department of Hematology, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands. Jak M; Department of Hematology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands. van Doesum JA; Department of Hematology, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands. de Boer JW; Department of Hematology, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands. Niezink AGH; Department of Radiation Oncology, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands. Kos M; Cancer Center Amsterdam, 1105 AZ Amsterdam, The Netherlands.; Department of Medical Oncology, Amsterdam UMC Location University of Amsterdam, 1081 HV Amsterdam, The Netherlands. Vermaat JSP; Department of Hematology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands. Sijs-Szabo A; Department of Hematology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands. van der Poel MWM; Department of Internal Medicine, Division of Hematology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, 6229 HX Maastricht, The Netherlands. Nijhof IS; Cancer Center Amsterdam, 1105 AZ Amsterdam, The Netherlands.; Department of Hematology, Amsterdam UMC Location Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands.; Department of Internal Medicine-Hematology, St Antonius Hospital, 3435 CM Nieuwegein, The Netherlands. Kuipers MT; Cancer Center Amsterdam, 1105 AZ Amsterdam, The Netherlands.; Department of Hematology, Amsterdam UMC Location Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands. Chamuleau MED; Cancer Center Amsterdam, 1105 AZ Amsterdam, The Netherlands.; Department of Hematology, Amsterdam UMC Location Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands. Lugtenburg PJ; Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands. Doorduijn JK; Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands. Serroukh YIM; Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands. Minnema MC; Department of Hematology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands. vanMeertenT; Department of Hematology, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands. Kersten MJ; Department of Hematology, Amsterdam UMC Location University of Amsterdam, 1007 MB Amsterdam, The Netherlands.; Cancer Center Amsterdam, 1105 AZ Amsterdam, The Netherlands.; LYMMCARE (Lymphoma and Myeloma Center Amsterdam), 1105 AZ Amsterdam, The Netherlands.
PRIMARY OVERALL SURVIVAL ANALYSIS OF THE PHASE 3 RANDOMIZED ZUMA‐7 STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA.
CD20 positive CD8 T cells are a unique and transcriptionally-distinct subset of T cells with distinct transmigration properties.
Autorzy:
Vlaming M; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. . Bilemjian V; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Freile JÁ; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Lourens HJ; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. van Rooij N; Department of Obstetrics and Gynecology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Huls G; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. vanMeertenT; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. de Bruyn M; Department of Obstetrics and Gynecology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Bremer E; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2021 Oct 15; Vol. 11 (1), pp. 20499. Date of Electronic Publication: 2021 Oct 15.
Timely administration of tocilizumab improves outcome of hospitalized COVID-19 patients.
Autorzy:
Rutgers A; Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, The Netherlands. Westerweel PE; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands. van der Holt B; HOVON Data Center, Department of Haematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. Postma S; Department of Haematology, University Medical Center Groningen, Groningen, The Netherlands. van Vonderen MGA; Department of Internal Medicine, Medical Center Leeuwarden, Leeuwarden, The Netherlands. Piersma DP; Department of Internal Medicine, Medisch Spectrum Twente, Enschede, The Netherlands. Postma D; Department of Internal Medicine, University Medical Center Groningen, Groningen, The Netherlands. van den Berge M; Department of Pulmonology, University Medical Center Groningen, Groningen, The Netherlands. Jong E; Department of Infectious Diseases, Meander MC, Amersfoort, The Netherlands. de Vries M; Department of Pulmonology, Tjongerschans Hospital, Heerenveen, The Netherlands. van der Burg L; Department of Internal Medicine, Antonius Hospital Sneek, Sneek, The Netherlands. Huugen D; Department of Internal Medicine, Deventer Hospital, Deventer, The Netherlands. van der Poel M; Department of Internal Medicine, Maastricht University Medical Centre+, Maastricht, The Netherlands. Kampschreur LM; Department of Internal Medicine, Medical Center Leeuwarden, Leeuwarden, The Netherlands. Nijland M; Department of Haematology, University Medical Center Groningen, Groningen, The Netherlands. Strijbos JH; Department of Pulmonology, Nij Smellinghe Hospital, Drachten, The Netherlands. Tamminga M; Department of Pulmonology, University Medical Center Groningen, Groningen, The Netherlands. Mutsaers PGNJ; Department of Haematology, Erasmus Medical Center, Rotterdam, The Netherlands. Schol-Gelok S; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands.; Department of Emergency Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands. Dijkstra-Tiekstra M; Department of Haematology, University Medical Center Groningen, Groningen, The Netherlands. Sidorenkov G; Department of Epidemiology, University Medical Center Groningen, Groningen, The Netherlands. Vincenten J; Department of Pulmonology, Albert Schweitzer Hospital, Dordrecht, The Netherlands. van Geffen WH; Department of Pulmonology, Medical Center Leeuwarden, Leeuwarden, The Netherlands. Knoester M; Department of Medical Microbiology, University Medical Center Groningen, Groningen, The Netherlands. Kosterink J; Pharmacy, University Medical Center Groningen, Groningen, The Netherlands. Gans R; Department of Internal Medicine, University Medical Center Groningen, Groningen, The Netherlands. Stegeman C; Department of Internal Medicine, University Medical Center Groningen, Groningen, The Netherlands. Huls G; Department of Haematology, University Medical Center Groningen, Groningen, The Netherlands. vanMeertenT; Department of Haematology, University Medical Center Groningen, Groningen, The Netherlands.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2022 Aug 12; Vol. 17 (8), pp. e0271807. Date of Electronic Publication: 2022 Aug 12 (Print Publication: 2022).
CD47-SIRPα blocking-based immunotherapy: Current and prospective therapeutic strategies.
Autorzy:
Bouwstra R; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. vanMeertenT; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Bremer E; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity.
Autorzy:
Cendrowicz E; University of Groningen, University Medical Center Groningen, Department of Hematology, Hanzeplein 1, 9713, GZ, Groningen, The Netherlands. Jacob L; University of Groningen, University Medical Center Groningen, Department of Hematology, Hanzeplein 1, 9713, GZ, Groningen, The Netherlands.; Kahr Medical Ltd, 1 Kiryat Hadassah POB 9779, 9109701, Jerusalem, Israel. Greenwald S; Kahr Medical Ltd, 1 Kiryat Hadassah POB 9779, 9109701, Jerusalem, Israel. Tamir A; Kahr Medical Ltd, 1 Kiryat Hadassah POB 9779, 9109701, Jerusalem, Israel. Pecker I; Kahr Medical Ltd, 1 Kiryat Hadassah POB 9779, 9109701, Jerusalem, Israel. Tabakman R; Kahr Medical Ltd, 1 Kiryat Hadassah POB 9779, 9109701, Jerusalem, Israel. Ghantous L; Departments of Nephrology and Hypertension, Hadassah Medical Center, Faculty of Medicine, Hebrew University, Jerusalem, Israel. Tamir L; Kahr Medical Ltd, 1 Kiryat Hadassah POB 9779, 9109701, Jerusalem, Israel. Kahn R; Kahr Medical Ltd, 1 Kiryat Hadassah POB 9779, 9109701, Jerusalem, Israel. Avichzer J; Kahr Medical Ltd, 1 Kiryat Hadassah POB 9779, 9109701, Jerusalem, Israel. Aronin A; Kahr Medical Ltd, 1 Kiryat Hadassah POB 9779, 9109701, Jerusalem, Israel. Amsili S; Kahr Medical Ltd, 1 Kiryat Hadassah POB 9779, 9109701, Jerusalem, Israel. Zorde-Khvalevsky E; Goldyne Savad Institute of Gene Therapy, Hebrew University Hospital, Jerusalem, Israel. Gozlan Y; Kahr Medical Ltd, 1 Kiryat Hadassah POB 9779, 9109701, Jerusalem, Israel. Vlaming M; University of Groningen, University Medical Center Groningen, Department of Hematology, Hanzeplein 1, 9713, GZ, Groningen, The Netherlands. Huls G; University of Groningen, University Medical Center Groningen, Department of Hematology, Hanzeplein 1, 9713, GZ, Groningen, The Netherlands. vanMeertenT; University of Groningen, University Medical Center Groningen, Department of Hematology, Hanzeplein 1, 9713, GZ, Groningen, The Netherlands. Dranitzki ME; Departments of Nephrology and Hypertension, Hadassah Medical Center, Faculty of Medicine, Hebrew University, Jerusalem, Israel. Foley-Comer A; Kahr Medical Ltd, 1 Kiryat Hadassah POB 9779, 9109701, Jerusalem, Israel. Pereg Y; Kahr Medical Ltd, 1 Kiryat Hadassah POB 9779, 9109701, Jerusalem, Israel. Peled A; Goldyne Savad Institute of Gene Therapy, Hebrew University Hospital, Jerusalem, Israel. Chajut A; Kahr Medical Ltd, 1 Kiryat Hadassah POB 9779, 9109701, Jerusalem, Israel. . Bremer E; University of Groningen, University Medical Center Groningen, Department of Hematology, Hanzeplein 1, 9713, GZ, Groningen, The Netherlands. .
The Implementation of TNFRSF Co-Stimulatory Domains in CAR-T Cells for Optimal Functional Activity.
Autorzy:
He Y; Department of Basic Medicine, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, China. Vlaming M; Department of Hematology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands. vanMeertenT; Department of Hematology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands. Bremer E; Department of Hematology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2022 Jan 08; Vol. 14 (2). Date of Electronic Publication: 2022 Jan 08.
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
